EMEA’s new system for fast-tracking drugs aims to offer quicker access to promising new therapies without jeopardising essential research. Draft Guidance on the use of the new conditional marketing approval procedure will shortly be published, [more]
Late last year, US patients with advanced renal cell cancer gained access to an oral multi-kinase inhibitor, Nexavar (sorafinib) the first new drug approved for this disease in the last 10 years. Manufacturer Bayer [more]
John Smyth likes to get things done. Head of a major research centre and member of EMEA’s scientific advisory committee, he argues for closer cooperation between academia and industry. He also wants a stronger voice [more]